Compare Nihon Kohden Corp. with Similar Stocks
Dashboard
1
Weak Long Term Fundamental Strength with a 3.71% CAGR growth in Net Sales over the last 5 years
2
Poor long term growth as Net Sales has grown by an annual rate of 3.71% over the last 5 years
3
Flat results in Mar 26
4
With ROE of 8.32%, it has a fair valuation with a 1.35 Price to Book Value
5
Consistent Underperformance against the benchmark over the last 3 years
Stock DNA
Pharmaceuticals & Biotechnology
JPY 263,880 Million (Small Cap)
16.00
NA
0.00%
-0.12
9.26%
1.47
Revenue and Profits:
Net Sales:
47,405 Million
(Quarterly Results - Jun 2026)
Net Profit:
-756 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
0.1%
0%
0.1%
6 Months
-13.24%
0%
-13.24%
1 Year
-12.05%
0%
-12.05%
2 Years
-19.27%
0%
-19.27%
3 Years
-61.34%
0%
-61.34%
4 Years
-53.5%
0%
-53.5%
5 Years
-58.78%
0%
-58.78%
Nihon Kohden Corp. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
3.71%
EBIT Growth (5y)
-3.54%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.10
Sales to Capital Employed (avg)
1.18
Tax Ratio
26.90%
Dividend Payout Ratio
35.85%
Pledged Shares
0
Institutional Holding
0.74%
ROCE (avg)
17.81%
ROE (avg)
11.13%
Valuation key factors
Factor
Value
P/E Ratio
16
Industry P/E
Price to Book Value
1.35
EV to EBIT
11.28
EV to EBITDA
8.97
EV to Capital Employed
1.39
EV to Sales
0.93
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
12.30%
ROE (Latest)
8.32%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Mildly Bullish
Mildly Bullish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
Mildly Bullish
Bullish
Shareholding Snapshot : Jun 2017
Shareholding Compare (%holding) 
Majority shareholders
Foreign Institutions
Domestic Funds
Held in 0 Schemes (0%)
Foreign Institutions
Held by 1 Foreign Institutions (0.74%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Jun'26 - YoY
Jun'26
Jun'25
Change(%)
Net Sales
47,405.00
50,020.00
-5.23%
Operating Profit (PBDIT) excl Other Income
610.00
2,483.00
-75.43%
Interest
114.00
107.00
6.54%
Exceptional Items
0.00
-74.00
100.00%
Consolidate Net Profit
-756.00
194.00
-489.69%
Operating Profit Margin (Excl OI)
-20.60%
28.40%
-4.90%
USD in Million.
Net Sales
YoY Growth in quarter ended Jun 2026 is -5.23% vs 8.21% in Jun 2025
Consolidated Net Profit
YoY Growth in quarter ended Jun 2026 is -489.69% vs -74.67% in Jun 2025
Annual Results Snapshot (Consolidated) - Mar'26
Mar'26
Mar'25
Change(%)
Net Sales
235,099.00
225,424.00
4.29%
Operating Profit (PBDIT) excl Other Income
24,604.00
24,904.00
-1.20%
Interest
341.00
144.00
136.81%
Exceptional Items
-3,241.00
-834.00
-288.61%
Consolidate Net Profit
14,570.00
14,098.00
3.35%
Operating Profit Margin (Excl OI)
79.90%
91.90%
-1.20%
USD in Million.
Net Sales
YoY Growth in year ended Mar 2026 is 4.29% vs 1.55% in Mar 2025
Consolidated Net Profit
YoY Growth in year ended Mar 2026 is 3.35% vs -17.20% in Mar 2025
About Nihon Kohden Corp. 
Nihon Kohden Corp.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






